Obesity promotes metabolic syndrome. GLP-1 agonists like tirzepatide simultaneously correct several components.
Understanding Metabolic Syndrome
Metabolic syndrome is defined by the presence of at least 3 of the following 5 criteria: waist circumference greater than 94 cm (men) or 80 cm (women), triglycerides greater than 1.5 g/L, HDL-cholesterol less than 0.40 g/L (men) or 0.50 g/L (women), blood pressure greater than 130/85 mmHg, and fasting glucose greater than 1 g/L. This syndrome increases the risk of type 2 diabetes by 5 times and cardiovascular risk by 2 times.
Obesity, particularly abdominal (visceral) obesity, is the central factor in metabolic syndrome. Visceral fat produces pro-inflammatory cytokines (TNF-alpha, IL-6) and deleterious adipokines that perpetuate insulin resistance, dyslipidemia, and hypertension. GLP-1 agonists, by reducing visceral fat mass, address the problem at its root.
Impact of Tirzepatide on Syndrome Components
- Weight loss: -22.5% at 15 mg (SURMOUNT-1), waist circumference reduction of 14.5 cm
- Blood glucose: HbA1c reduction of 2.1% in diabetic patients
- Triglycerides: 25 to 35% reduction in clinical trials
- Blood pressure: 5 to 8 mmHg systolic reduction
- HDL-cholesterol: modest but significant increase
Towards a Resolution of Metabolic Syndrome
The SURMOUNT trial data show that a significant proportion of patients treated with tirzepatide no longer meet the criteria for metabolic syndrome after 72 weeks of treatment. This “resolution” of metabolic syndrome is associated with a major reduction in long-term cardiovascular risk. This is an additional argument for considering obesity as a disease to be treated medically.
Track your progress with the MounjaGO application.
FAQ
What are the main recommendations for obesity under GLP-1 treatment?
Key recommendations include regular medical follow-up, monitoring blood tests, adequate protein intake, and adapted physical activity. Consult your doctor for personalized advice for your situation.
Is tirzepatide (Mounjaro) effective as a GLP-1 agonist?
The SURMOUNT and SURPASS clinical trials have demonstrated the efficacy of tirzepatide in this indication, with significant documented results. Your doctor will evaluate the relevance of the treatment for your individual profile.
What side effects should be monitored during GLP-1 treatment for obesity?
Side effects to monitor depend on your personal situation. The most common are gastrointestinal disorders (nausea, diarrhea, constipation). Report any unusual symptoms to your doctor for evaluation.
How does the MounjaGO application help with obesity?
MounjaGO offers comprehensive tracking of injections, weight, side effects, and generates PDF reports for your consultations. This structured monitoring improves therapeutic adherence and communication with your doctor.